Protagonist Therapeutics将在第二季度启动的90天窗口期内退出与武田就Rusfertide达成的50:50利润分成协议

美股速递
Feb 26

生物制药公司Protagonist Therapeutics Inc(纳斯达克代码:PTGX)宣布,计划在预计于今年第二季度开放的90天选择窗口期内,行使其权利,退出与合作伙伴武田制药就实验性药物Rusfertide所签订的50:50利润分成安排。

此举意味着Protagonist Therapeutics将重新获得Rusfertide在全球范围内的全部开发和商业化权利。Rusfertide是一种用于治疗真性红细胞增多症等血液疾病的在研疗法。公司表示,这一战略性决策旨在最大化该药物的潜在价值,并为其未来发展提供更大的灵活性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10